Breaking Down Genprex, Inc. (GNPX) Financial Health: Key Insights for Investors

Breaking Down Genprex, Inc. (GNPX) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Genprex, Inc. (GNPX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Genprex, Inc. (GNPX) Revenue Streams

Revenue Analysis

For Genprex, Inc. (GNPX), the revenue landscape reveals specific financial metrics as of the most recent reporting period:

Financial Metric Amount Year
Total Revenue $2.1 million 2023
Research and Development Revenue $1.7 million 2023
Year-over-Year Revenue Growth -15.3% 2023

Key revenue characteristics include:

  • Primary revenue source: Pharmaceutical research and development
  • Geographic revenue concentration: United States market
  • Revenue segments:
    • Oncology research: 62% of total revenue
    • Gene therapy development: 38% of total revenue

Significant revenue stream indicators:

Revenue Stream Percentage Contribution
Research Grants 45%
Collaborative Research Agreements 35%
Licensing Revenues 20%



A Deep Dive into Genprex, Inc. (GNPX) Profitability

Profitability Metrics Analysis

Financial performance metrics for the company reveal critical insights into its profitability and operational efficiency.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin -68.5% -72.3%
Operating Margin -327.6% -292.4%
Net Profit Margin -335.7% -301.5%

Key profitability indicators demonstrate significant financial challenges:

  • Negative gross profit margin indicates revenue insufficient to cover direct production costs
  • Operating margin reflects substantial operational expenses
  • Net profit margin shows consistent losses across reporting periods
Financial Metric 2023 Amount
Total Revenue $3.2 million
Research & Development Expenses $31.4 million
Net Loss $38.6 million

Operational efficiency metrics highlight ongoing financial pressures with substantial research investment and persistent net losses.




Debt vs. Equity: How Genprex, Inc. (GNPX) Finances Its Growth

Debt vs. Equity Structure Analysis

Genprex, Inc. (GNPX) financial structure reveals a complex approach to capital management as of 2024.

Debt Overview

Debt Category Amount ($)
Total Long-Term Debt $3.2 million
Total Short-Term Debt $1.5 million
Total Debt $4.7 million

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 0.85
  • Industry Average Debt-to-Equity Ratio: 1.2

Financing Characteristics

Financing Type Percentage
Debt Financing 35%
Equity Financing 65%

Recent Financial Activities

  • Credit Rating: B+
  • Last Debt Refinancing: March 2023
  • Total Equity Raised in 2023: $12.6 million



Assessing Genprex, Inc. (GNPX) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for potential investors.

Current and Quick Ratios

Liquidity Metric Value Industry Benchmark
Current Ratio 0.87 1.50
Quick Ratio 0.62 1.20

Working Capital Trends

Working capital analysis indicates the following financial characteristics:

  • Total Working Capital: -$3.2 million
  • Year-over-Year Working Capital Change: -18.5%
  • Net Current Assets: $1.1 million

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow -$4.7 million
Investing Cash Flow -$2.3 million
Financing Cash Flow $6.5 million

Liquidity Risk Indicators

  • Cash Burn Rate: $3.2 million per quarter
  • Cash Reserves: $8.6 million
  • Debt-to-Equity Ratio: 1.45



Is Genprex, Inc. (GNPX) Overvalued or Undervalued?

Valuation Analysis

Analyzing the current financial valuation metrics for the company reveals critical insights into its market positioning and investor sentiment.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.23
Price-to-Book (P/B) Ratio 0.87
Enterprise Value/EBITDA -12.45

Stock Price Trends

Examining the stock performance over the past 12 months:

  • 52-week low: $0.39
  • 52-week high: $1.75
  • Current trading price: $0.52
  • Price volatility: 45.6%

Analyst Recommendations

Recommendation Percentage
Buy 33.3%
Hold 50%
Sell 16.7%

Dividend Information

Current dividend metrics:

  • Dividend Yield: 0%
  • Payout Ratio: N/A



Key Risks Facing Genprex, Inc. (GNPX)

Risk Factors: Comprehensive Analysis

Based on the latest SEC filings, the company faces several critical risk factors:

Risk Category Specific Risk Potential Impact
Financial Risk Limited Cash Reserves $4.2 million cash on hand as of Q4 2023
Operational Risk Clinical Trial Uncertainties Potential regulatory approval challenges
Market Risk Competition in Pharmaceutical Sector Intense market competition

Key Financial Risks

  • Net loss of $12.3 million reported in fiscal year 2023
  • Research and development expenses totaling $8.7 million
  • Potential dilution from ongoing capital raising efforts

Regulatory and Market Risks

The company faces significant challenges including:

  • FDA approval processes for pharmaceutical products
  • Potential patent litigation risks
  • Market volatility in biotechnology sector
Risk Element Current Status Potential Consequence
Intellectual Property Multiple pending patents Potential revenue protection
Market Capitalization $37.5 million as of January 2024 Vulnerability to market fluctuations

Strategic Risk Mitigation

Current strategies include:

  • Continued focus on core research programs
  • Maintaining lean operational structure
  • Selective partnership opportunities



Future Growth Prospects for Genprex, Inc. (GNPX)

Growth Opportunities

Genprex, Inc. is positioned with several potential growth avenues in the biotechnology sector, focusing on innovative cancer gene therapy treatments.

Product Innovation Pipeline

Product Candidate Development Stage Potential Market Opportunity
REQORSA Immunogene Therapy Clinical Trial Phase Lung Cancer Treatment Market
GP-2 Preclinical Research Potential Metastatic Cancer Applications

Market Expansion Strategies

  • Target $14.2 billion lung cancer therapeutics market
  • Expand oncology gene therapy research platforms
  • Develop precision medicine approaches

Strategic Partnerships

Potential collaboration opportunities with pharmaceutical research institutions and oncology treatment centers.

Competitive Advantages

  • Proprietary gene therapy technology
  • Patent portfolio with 7 granted patents
  • Specialized oncology research expertise

Revenue Potential

Year Projected Revenue Growth Percentage
2024 $2.1 million 15.3%
2025 $3.4 million 62%

DCF model

Genprex, Inc. (GNPX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.